FINWIRES · TerminalLIVE
FINWIRES

Solstice Advanced Materials' Electronic Materials, Refrigerants Drive Growth Outlook, RBC Says

By

Solstice Advanced Materials (SOLS) could raise its fiscal 2026 guidance after another expected Q2 EBITDA beat, driven by strength in electronic materials and refrigerants, RBC Capital Markets said in a note Monday.

The investment firm noted demand for electronic materials continues to benefit from artificial intelligence and chip fab equipment, while refrigerants volumes also continue to see strong trends.

Analysts expect Q2 EBITDA to exceed consensus by about 5%, similar to its Q1 beat.

The firm said the company's longer-term growth outlook remains supported by planned capacity expansions across nuclear, electronic materials and ballistic fibers.

RBC Capital Markets maintained its outperform rating on Solstice Advanced Materials and raised its price target to $102 from $100.

Shares of the company were up 7.9% in Tuesday trading.

Price: $89.10, Change: $+6.56, Percent Change: +7.94%

Related Articles

Wire

Genmab Says Epcoritamab Combination Boosts Progression-Free Survival in Phase 3 Lymphoma Trial

Genmab (GMAB) said that a Phase 3 study of epcoritamab combined with lenalidomide met its primary objective, helping adults with relapsed or refractory diffuse large B-cell lymphoma stay progression-free longer than those receiving standard therapy.The regimen cut the risk of disease progression or death by 60% under US censoring rules and 56% under censoring rules used outside the US, with both results statistically significant, Genmab said Monday in a statement.Genmab said the safety profile was consistent with what's known for each drug. The company and its partner, AbbVie (ABBV), plan to discuss the findings with global regulators.The ongoing Phase 3 trial is enrolling adults who received at least one prior systemic therapy and were not eligible for stem-cell transplant or CAR-T treatment.Genmab shares rose 2.2% in after-hours trading, and AbbVie eased 0.2%.

$ABBV$GMAB
Wire

Mama's Creations Commences Proposed Common Stock Offering

Mama's Creations (MAMA) said late Monday it has commenced a proposed, underwritten public offering of its common stock.The company said it plans to grant the underwriters a 30-day option to buy up to an additional 15% of the shares offered.It intends to use the offering net proceeds for working capital and general corporate purposes, the company added.Shares of Mama's Creations were down more than 10% in after-hours activity.

$MAMA
Wire

Concentrix Fiscal Q2 Earnings Fall, Revenue Rises; FY Outlook Cut; Shares Tumble After Hours

Concentrix (CNXC) reported fiscal Q2 non-GAAP net income late Monday of $2.63 per diluted share, down from $2.70 a year earlier.Four analysts polled by FactSet expected $2.64.Revenue in the three months ended May 31 rose to $2.46 billion from $2.42 billion a year earlier.Four analysts expected $2.47 billion.Concentrix expects fiscal Q3 non-GAAP EPS of $2.65 to $2.77 on revenue of $2.47 billion to $2.49 billion.Four analysts project EPS of $3.09 on revenue of $2.53 billion.The company lowered full-year EPS guidance to $10.83 to $11.18 on revenue of $9.93 billion to $10.03 billion. The previous forecast pegged EPS at $11.48 to $12.07 on revenue of $10.04 billion to $10.18 billion.Four analysts expect EPS of $11.71 on revenue of $10.11 billion.Concentrix shares fell 26% in after-hours trading.The company maintained its quarterly dividend of $0.36 a share, payable Aug. 4, to stockholders of record July 24.

$CNXC